Thymalin 20mg

Thymalin is a polypeptide preparation originally isolated from calf thymus glands, developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It consists of a complex of small peptides that have been studied extensively in Russian clinical practice for immunomodulatory and geroprotective properties. The primary bioactive component is believed to be the dipeptide Glu-Trp, which has been studied independently as a thymic bioregulator. The mechanism of action involves modulation of T-cell maturation and differentiation pathways. The thymus is the primary organ responsible for T-cell development and education, but it undergoes progressive involution (shrinkage) with age, leading to diminished output of naive T-cells and gradual immune decline (immunosenescence). Thymalin research focuses on its ability to partially restore thymic function and improve T-cell populations. Khavinson et al. conducted a landmark 15-year longitudinal study in elderly patients (60-80 years) who received annual cycles of thymalin combined with epithalamin (the precursor of synthetic epitalon). The treated group showed significantly improved immune function, reduced incidence of acute respiratory infections, ischemic heart disease, hypertension, osteoporosis, and osteoarthritis, and remarkably, a 2-fold reduction in mortality rate compared to controls. While these results are striking, the study was conducted in Russia and may not have been subject to the same peer review standards as Western clinical trials.

Thymalin is a polypeptide preparation originally isolated from calf thymus glands, developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It consists of a complex of small peptides that have been studied extensively in Russian clinical practice for immunomodulatory and geroprotective properties. The primary bioactive component is believed to be the dipeptide Glu-Trp, which has been studied independently as a thymic bioregulator. The mechanism of action involves modulation of T-cell maturation and differentiation pathways. The thymus is the primary organ responsible for T-cell development and education, but it undergoes progressive involution (shrinkage) with age, leading to diminished output of naive T-cells and gradual immune decline (immunosenescence). Thymalin research focuses on its ability to partially restore thymic function and improve T-cell populations. Khavinson et al. conducted a landmark 15-year longitudinal study in elderly patients (60-80 years) who received annual cycles of thymalin combined with epithalamin (the precursor of synthetic epitalon). The treated group showed significantly improved immune function, reduced incidence of acute respiratory infections, ischemic heart disease, hypertension, osteoporosis, and osteoarthritis, and remarkably, a 2-fold reduction in mortality rate compared to controls. While these results are striking, the study was conducted in Russia and may not have been subject to the same peer review standards as Western clinical trials.

Russian clinical protocols used 10 mg daily intramuscularly for 5-10 day courses, often repeated annually. The 20mg vial provides material for research protocols.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.